Maju Mathews

1.8k total citations
73 papers, 1.0k citations indexed

About

Maju Mathews is a scholar working on Psychiatry and Mental health, Pharmacology and Clinical Psychology. According to data from OpenAlex, Maju Mathews has authored 73 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Psychiatry and Mental health, 23 papers in Pharmacology and 19 papers in Clinical Psychology. Recurrent topics in Maju Mathews's work include Schizophrenia research and treatment (38 papers), Treatment of Major Depression (22 papers) and Bipolar Disorder and Treatment (21 papers). Maju Mathews is often cited by papers focused on Schizophrenia research and treatment (38 papers), Treatment of Major Depression (22 papers) and Bipolar Disorder and Treatment (21 papers). Maju Mathews collaborates with scholars based in United States, Belgium and Germany. Maju Mathews's co-authors include Srihari Gopal, Carl Gommoll, René Núñez, Dalei Chen, Isaac Nuamah, Edward Kim, Adam Savitz, Mary Mackle, Suresh Durgam and Jennifer Kern Sliwa and has published in prestigious journals such as SHILAP Revista de lepidopterología, American Journal of Psychiatry and Biological Psychiatry.

In The Last Decade

Maju Mathews

69 papers receiving 1000 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Maju Mathews United States 18 702 300 204 126 104 73 1.0k
Thomas J. Arndt United States 8 760 1.1× 171 0.6× 147 0.7× 73 0.6× 57 0.5× 8 1.1k
Yangchun Du United States 16 617 0.9× 256 0.9× 117 0.6× 114 0.9× 103 1.0× 55 1.2k
S Martin United Kingdom 14 693 1.0× 248 0.8× 202 1.0× 122 1.0× 81 0.8× 24 1.0k
Dan Zimbroff United States 12 890 1.3× 266 0.9× 317 1.6× 147 1.2× 117 1.1× 21 1.3k
Judith C. Kando United States 15 741 1.1× 264 0.9× 135 0.7× 60 0.5× 199 1.9× 40 1.2k
Michelle Kramer United States 15 1.6k 2.3× 283 0.9× 254 1.2× 141 1.1× 172 1.7× 27 1.9k
Steven J. Romano United States 21 798 1.1× 239 0.8× 490 2.4× 114 0.9× 69 0.7× 32 1.6k
WFSBP Task Force on Treatment Guide United States 8 1.1k 1.5× 408 1.4× 274 1.3× 190 1.5× 110 1.1× 8 1.4k
David N. Osser United States 17 431 0.6× 226 0.8× 235 1.2× 122 1.0× 49 0.5× 51 775
James M. Eudicone United States 19 643 0.9× 227 0.8× 116 0.6× 87 0.7× 49 0.5× 69 958

Countries citing papers authored by Maju Mathews

Since Specialization
Citations

This map shows the geographic impact of Maju Mathews's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maju Mathews with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maju Mathews more than expected).

Fields of papers citing papers by Maju Mathews

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maju Mathews. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maju Mathews. The network helps show where Maju Mathews may publish in the future.

Co-authorship network of co-authors of Maju Mathews

This figure shows the co-authorship network connecting the top 25 collaborators of Maju Mathews. A scholar is included among the top collaborators of Maju Mathews based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maju Mathews. Maju Mathews is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mathews, Maju, Shashidhar Murthy, Vijaya Reddy, et al.. (2025). Primary Hyperparathyroidism: Clinical, Biochemical, and Radio-Pathological Profiles of 804 Patients – A Retrospective Study from South India. Indian Journal of Endocrinology and Metabolism. 29(1). 69–76.
2.
Fu, Dong‐Jing, et al.. (2023). Esketamine versus placebo on time to remission in major depressive disorder with acute suicidality. BMC Psychiatry. 23(1). 587–587. 10 indexed citations
3.
Morrens, Joachim, Maju Mathews, Vanina Popova, et al.. (2022). Use of Clinical Global Impressions-Severity (CGI-S) to Assess Response to Antidepressant Treatment in Patients with Treatment-Resistant Depression. Neuropsychiatric Disease and Treatment. Volume 18. 1127–1132. 12 indexed citations
4.
5.
Gopal, Srihari, et al.. (2020). <p>Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study</p>. Neuropsychiatric Disease and Treatment. Volume 16. 681–690. 3 indexed citations
6.
Mathews, Maju, Srihari Gopal, Isaac Nuamah, et al.. (2019). <p>Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia</p>. Neuropsychiatric Disease and Treatment. Volume 15. 1365–1379. 31 indexed citations
7.
Sliwa, Jennifer Kern, Adam Savitz, Isaac Nuamah, et al.. (2018). An assessment of injection site reaction and injection site pain of 1-month and 3-month long-acting injectable formulations of paliperidone palmitate. Perspectives In Psychiatric Care. 54(4). 530–538. 11 indexed citations
8.
9.
Thase, Michael E., John Edwards, Suresh Durgam, et al.. (2017). Effects of vilazodone on suicidal ideation and behavior in adults with major depressive disorder or generalized anxiety disorder. International Clinical Psychopharmacology. 32(5). 281–288. 11 indexed citations
10.
11.
Khan, Arif, Suresh Durgam, Xiongwen Tang, et al.. (2016). Post Hoc Analyses of Anxiety Measures in Adult Patients With Generalized Anxiety Disorder Treated With Vilazodone. The Primary Care Companion For CNS Disorders. 18(2). 3 indexed citations
12.
Findling, Robert L., Ronald Landbloom, Mary Mackle, et al.. (2015). Safety and Efficacy from an 8 Week Double-Blind Trial and a 26 Week Open-Label Extension of Asenapine in Adolescents with Schizophrenia. Journal of Child and Adolescent Psychopharmacology. 25(5). 384–396. 32 indexed citations
13.
14.
Gommoll, Carl, Maju Mathews, René Núñez, et al.. (2015). Vilazodone in patients with generalized anxiety disorder. International Clinical Psychopharmacology. 30(6). 297–306. 22 indexed citations
15.
Mathews, Maju, Carl Gommoll, Dalei Chen, René Núñez, & Arif Khan. (2014). Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder. International Clinical Psychopharmacology. 30(2). 67–74. 57 indexed citations
16.
Jain, Rakesh K., Dalei Chen, John Edwards, & Maju Mathews. (2013). Early and sustained improvement with vilazodone in adult patients with major depressive disorder: post hoc analyses of two phase III trials. Current Medical Research and Opinion. 30(2). 263–270. 12 indexed citations
17.
Hardy, Marcia, et al.. (2010). Terrestrial toxicity evaluation of decabromodiphenyl ethane on organisms from three trophic levels. Ecotoxicology and Environmental Safety. 74(4). 703–710. 16 indexed citations
18.
Adetunji, Babatunde, et al.. (2006). Detection and Management of Malingering in a Clinical Setting.. 13(1). 61–69. 15 indexed citations
19.
Mathews, Maju, et al.. (2005). The concept of insight in mental illness. 12(9). 58–61. 1 indexed citations
20.
Martin, Andrés, Walter Gilliam, Joseph M. Rey, et al.. (2005). Child psychopharmacology, effect sizes, and the big bang [14] (multiple letters). American Journal of Psychiatry. 162(4). 817–819. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Thomas J. Arndt Breakdown of academic impact, for papers by Yangchun Du Breakdown of academic impact, for papers by S Martin Breakdown of academic impact, for papers by Dan Zimbroff Breakdown of academic impact, for papers by Judith C. Kando Breakdown of academic impact, for papers by Michelle Kramer Breakdown of academic impact, for papers by Steven J. Romano Breakdown of academic impact, for papers by WFSBP Task Force on Treatment Guide Breakdown of academic impact, for papers by David N. Osser Breakdown of academic impact, for papers by James M. Eudicone
Rankless by CCL
2026